Investing.comQwen · 实盘不做把握 3/10不做原因:无法执行
北京时间·🕒 发布 20:04:34·⟳ 抓取 20:05:52 +1m18s·⚡ 决策 09-03 20:14:11 +8m19s·54.2 天前
Modular Medical获FDA批准Pivot胰岛素贴片泵软件增强，商业化前里程碑
MODD市值仅$2820万、日均成交$127万、盘前买卖价差近10%，流动性不足以执行任何有意义的仓位；事件本身仅为已获批器械的软件增强（非新器械510k/PMA），催化强度有限且盘前已反应+7%；无跨市场受益标的
📄 原文Investing.com↗ 原文
Modular Medical receives FDA clearance for Pivot pump software
Oil pulls back, Broadcom disappoints - what’s moving markets SAN DIEGO - Modular Medical, Inc. (NASDAQ:MODD) announced…
不做 Modular Medical（MODD.US）
不可执行：市值$2820万、日均成交$127万、盘前价差9.6%（$3.53/$3.87），任何有意义仓位都无法以合理成本进出；事件仅为已获批器械软件增强（非新审批），催化强度有限且盘前已+7%；20日波动率11.4%使止损不可靠
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Modular Medical（MODD.US）获FDA批准Pivot泵软件增强，属已获批器械的小幅迭代而非新审批。公司市值仅$2820万，日均成交约$127万，盘前已涨7%且买卖价差达9.6%（$3.53/$3.87），实际执行成本极高。20日波动率11.4%，近期单日涨跌幅达±33%，风控无法可靠执行。事件催化强度（软件更新）与执行摩擦（流动性、价差、波动）严重不匹配，无正期望交易结构
🔎 新鲜度:最早出现 2026-09-03 · 扩散 low · price-in 风险 medium ↗
主要风险
- 市值$2820万、日均成交$127万、买卖价差近10%，任何仓位都面临极高执行成本和滑点
- 20日实现波动率11.4%，单日波动可达±30%，止损不可靠
先例如何影响了这次决策
对本次决策的影响:先例缺失不影响结论——标的流动性本身已否决交易
方向:无可用先例
涨幅量级:无法校准
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 797 ms
{"result": "search_processed_events:agent query=`modd fda software enhancement insulin pump | modular medical fda clearance pivot pump software`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、7389 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 1,343 ms
{
原文全文
展开原文 · 1,667 字
Oil pulls back, Broadcom disappoints - what’s moving markets
SAN DIEGO - Modular Medical, Inc. (NASDAQ:MODD) announced today that the U.S. Food and Drug Administration has cleared software enhancements for its Pivot tubeless patch pump insulin delivery system, according to a press release statement.
The clearance includes improvements to bolus dosing flexibility, user interface enhancements, and other software upgrades. The updates allow users to customize the amount of insulin delivered with each button push.
The company stated the clearance was received ahead of its planned fourth quarter 2026 commercial launch. Jeb Besser, Chief Executive Officer, said the improvements represent the first in a series of planned enhancements to the Pivot platform.
The Pivot tubeless patch pump is designed to provide continuous subcutaneous insulin infusion with both basal and bolus insulin delivery over a three-day wear period. The system is intended for people living with diabetes as an alternative to multiple daily injections.
Modular Medical is a commercial-stage medical device company focused on insulin delivery technology. The company was founded by Paul DiPerna, who previously founded Tandem Diabetes in 2005 and designed its t:slim insulin pump.
The company’s press release contained forward-looking statements regarding the planned commercial launch and future product improvements, noting that actual results could differ materially due to various risk factors including manufacturing capabilities, market acceptance, and regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN DIEGO - Modular Medical, Inc. (NASDAQ:MODD) announced today that the U.S. Food and Drug Administration has cleared software enhancements for its Pivot tubeless patch pump insulin delivery system, according to a press release statement.
The clearance includes improvements to bolus dosing flexibility, user interface enhancements, and other software upgrades. The updates allow users to customize the amount of insulin delivered with each button push.
The company stated the clearance was received ahead of its planned fourth quarter 2026 commercial launch. Jeb Besser, Chief Executive Officer, said the improvements represent the first in a series of planned enhancements to the Pivot platform.
The Pivot tubeless patch pump is designed to provide continuous subcutaneous insulin infusion with both basal and bolus insulin delivery over a three-day wear period. The system is intended for people living with diabetes as an alternative to multiple daily injections.
Modular Medical is a commercial-stage medical device company focused on insulin delivery technology. The company was founded by Paul DiPerna, who previously founded Tandem Diabetes in 2005 and designed its t:slim insulin pump.
The company’s press release contained forward-looking statements regarding the planned commercial launch and future product improvements, noting that actual results could differ materially due to various risk factors including manufacturing capabilities, market acceptance, and regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。